Abstract
LONZA HAS BEEN UNDERGOING A strategic reorientation over past year. It's a transformation that has involved divesting noncore energy and polymer intermediates businesses, developing a new vision statement, and restructuring into the preeminent supplier to life sciences industry through chemical and biotechnology platforms driven by an unrelenting passion. Today, more than 80% of its activities are directed toward life sciences. Nowhere is unrelenting passion clearer than in Markus Gemuend, a 14-year veteran of Lonza who took over as chief executive officer on Feb. 1. The tall, boyish-looking 43-year-old head of company's fast-growing biologies division was tapped to succeed Sergio Marchionne, who oversaw divestitures and is now vice chairman of board. Gemuend also remains head of biologies division. Gemuend spoke about Lonza's metamorphosis last month at annual Synthetic Organic Chemical Manufacturers Association luncheon in New York City. Custom manufacturing is a...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
